Machine learning for catalysing the integration of noncoding RNA in research and clinical practice.
Artificial intelligence
Biomarker
Machine learning
Molecular pathways
Noncoding RNA
Personalised medicine
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
18 Jul 2024
18 Jul 2024
Historique:
received:
08
03
2024
revised:
17
06
2024
accepted:
02
07
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
19
7
2024
Statut:
aheadofprint
Résumé
The human transcriptome predominantly consists of noncoding RNAs (ncRNAs), transcripts that do not encode proteins. The noncoding transcriptome governs a multitude of pathophysiological processes, offering a rich source of next-generation biomarkers. Toward achieving a holistic view of disease, the integration of these transcripts with clinical records and additional data from omic technologies ("multiomic" strategies) has motivated the adoption of artificial intelligence (AI) approaches. Given their intricate biological complexity, machine learning (ML) techniques are becoming a key component of ncRNA-based research. This article presents an overview of the potential and challenges associated with employing AI/ML-driven approaches to identify clinically relevant ncRNA biomarkers and to decipher ncRNA-associated pathogenetic mechanisms. Methodological and conceptual constraints are discussed, along with an exploration of ethical considerations inherent to AI applications for healthcare and research. The ultimate goal is to provide a comprehensive examination of the multifaceted landscape of this innovative field and its clinical implications.
Identifiants
pubmed: 39029428
pii: S2352-3964(24)00283-4
doi: 10.1016/j.ebiom.2024.105247
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
105247Informations de copyright
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests YD holds patents and licensing agreements related to the use of RNAs for diagnostic and therapeutic purposes and is Scientific Advisory Board (SAB) member of Firalis SA. The other authors declare no competing interests.